Sinensetin
1. Identity: Chemical and Botanical Profile
Chemical Name and Structure
Sinensetin is a pentamethoxyflavone, chemically known as 2-(3,4-dimethoxyphenyl)-5,6,7-trimethoxy-4H-1-benzopyran-4-one. The flavone skeleton is substituted by methoxy groups at positions 5, 6, 7, 3′, and 4′, respectively, with a molecular formula of C20H20O7 and a molecular weight of 372.4 g/mol. A polymethoxylated flavonoid of this class has a double bond between positions 2 and 3, and a ketone at position 4 of the C ring.
Polymethoxyflavones (PMFs) are a type of uncommon dietary flavonoids characterized by more than one methoxy group, which exist in limited plant species such as Citrus species and Kaempferia parviflora. Different PMFs—including nobiletin, sinensetin, tangeretin, and casticin—have been isolated from these natural sources.
Botanical Sources and Distribution
Sinensetin is a polymethoxylated flavonoid found in Orthosiphon aristatus var. aristatus [syn: Orthosiphon stamineus Benth., Orthosiphon spicatus (Thunb.) Backer, Bakh.f. & Steenis] (Lamiaceae) and in many citrus fruits. In citrus fruits, it is particularly more abundant in the peel than in other parts of the fruit.
Nobiletin (5,6,7,8,3′,4′-hexamethoxyflavone), tangeretin (5,6,7,8,4′-pentamethoxyflavone), and sinensetin (5,6,7,3′,4′-pentamethoxyflavone) are the most common PMFs found in citrus peel extract. Citrus species that have been reported to contain sinensetin include Citrus sinensis (sweet orange). A study by Kawaii et al. (1999) quantified 25 flavonoids in several citrus species, revealing that sweet orange, compared to bitter orange, was enriched in sinensetin, among other flavonoids.
Sinensetin is also derived from Schisandra sphenanthera and is a major component of a traditional medicine involving this plant.
Common Forms and Preparations
The herbal material (Orthosiphon stamineus leaves) contains 0.5–0.7% flavonoids, especially methoxylated flavones including eupatorin, eupatorin methyl ether, rhamnazin, scutellarein tetramethyl ether, sinensetin, and salvigenin.
The European Medicines Agency (EMA) HMPC monograph on Orthosiphon stamineus folium (Java tea) recognizes the following herbal preparations: dried, fragmented leaf; liquid extract (DER 1:1, ethanol 25% m/m); dry extract (DER 5–7:1, water); dry extract (DER 8–12:1, ethanol 60% V/V); and dry extract (DER 7–8:1, ethanol 70% V/V).
In a phytochemical study, the contents of sinensetin (SEN) in a 95% ethanolic extract of O. stamineus were quantified at 0.94% by HPLC. As a research material and dietary supplement ingredient, sinensetin is also available as an isolated pure compound, typically obtained by solvent extraction from plant material, or by chemical synthesis—one reported synthesis proceeds via alkaline condensation and methylation of 5,6,7,3′,4′-pentahydroxyflavone using dimethyl sulphate and potassium carbonate.
2. Traditional and Historical Use
Southeast Asian Ethnomedicinal Use
Orthosiphon stamineus has long been used in traditional medicine in East India, Indo China, Southeast Asia, and tropical regions of Australia where the plant is commonly found. It is commonly known as "cat's whiskers" or "misai kucing" and is a popular medicinal herb in Southeast Asia.
Orthosiphon aristatus is widely employed in traditional medicine as a diuretic and to treat hypertension, rheumatism, tonsillitis, gout, menstrual disorder, and diabetes. Locally known as "Misai Kucing" (cat's whiskers), the plant is used in Southeast Asia to treat various inflammatory diseases such as cancer, hepatitis, rheumatism, abdominal pain, psoriasis, hyperlipidemia, diabetes, and kidney stones.
Orthosiphon stamineus is an indigenous medicinal plant of Southeast Asia that has been traditionally used in the treatment of rheumatoid arthritis, gout, and other inflammatory disorders.
Orthosiphon aristatus is a traditional folk medicine extensively used in Southeast Asia because of its various pharmacological effects, including antioxidant, antitumor, and hypoglycemic activities.
European Use and Regulatory Recognition
In Europe, people use a decoction of leaves of O. stamineus to make java tea to improve general health and fitness.
The HMPC monograph (EMA) grants traditional-use status for increasing urine volume and irrigation of the urinary tract for mild bladder complaints. The ESCOP monograph covers irrigation of the urinary tract for inflammation and kidney gravel, as a supportive measure for bacterial infections of the urinary tract. The German Commission E monograph approves its irrigation use for bacterial and inflammatory diseases of the urinary tract and for kidney gravel.
The EMA HMPC community herbal monograph concludes that the herbal preparation can be traditionally used to increase urine production for minor urinary tract complaints.
Additional therapeutic indications recognized by European regulatory bodies include: "traditionally used to facilitate urinary and digestive elimination functions," "traditionally used to promote the renal elimination of water," and "traditionally used as an adjuvant to slimming regimes."
For the dried plant material, a recommended posology cited in the EMA assessment report is an infusion of 2–3 g of dried material in 150 mL of water, two to three times per day.
Indonesian Official Recognition
Orthosiphon stamineus is widely used as an ingredient in traditional medicine and functional food in Indonesia, partially for its main active compound, sinensetin. The Indonesia Ministry of Health has included it among its "Eleven Scientific Herbal Medicines" (Jamu Saintifik), as documented by the Center for Research and Development of Medicinal Plants and Traditional Medicines.
3. Key Constituents and Active Compounds of the Source Plant
The wide spectrum of therapeutic properties of O. stamineus is largely attributable to the complexity and diversity of its phytochemical constituents. Several components have been isolated, including phenolics, flavonoids, terpenoids, organic acids, and essential oils. However, most of the therapeutic action is attributed to certain active constituents, including eupatorin (EUP), rosmarinic acid (RA), sinensetin (SEN), and 3-hydroxy-5,6,7,4′-tetramethoxyflavone (TMF).
Phytochemical investigations of O. stamineus have revealed the presence of numerous bioactive compounds, including orthosiphols F–H and J, staminols A and B, staminolactones A and B, norstaminol A, sinensetin, 5-hydroxy-6,7,3′,4′-tetramethoxyflavone, salvigenin, tetramethylscutellarein, vomifoliol, aurantiamide acetate, rosmarinic acid, caffeic acid, oleanolic acid, ursolic acid, betulinic acid, and β-sitosterol.
Phytochemical studies have reported approximately 116 compounds isolated from O. stamineus, classified as monoterpenes, diterpenes, triterpenes, saponins, flavonoids, essential oil, and organic acids.
4. Mechanisms of Action
Anti-inflammatory Pathways
Sinensetin inhibits NF-κB activation by inhibiting degradation or stabilizing IκB-α, suppressing excessive inflammation with no effect on MAPK phosphorylation. Pre-treating LPS-stimulated RAW 264.7 macrophage cells for 1 hour inhibited secretion of NO and protein expression of iNOS and COX-2 in a dose-dependent manner.
Sinensetin inhibited the expressions of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) at the protein level, and interleukin (IL)-6, IL-1β, and tumor necrosis factor-α (TNF-α) at the mRNA level. In vitro and in vivo experiments showed that NF-κB was the key target of sinensetin in its anti-inflammatory effect.
In influenza A virus-infected A549 cells, sinensetin treatment significantly decreased IAV-induced expression of pro-inflammatory mediators including IL-6, TNF-α, IP-10, IL-8, and MCP-1. Levels of COX-2 and prostaglandin E2 (PGE2) upregulated by IAV infection were dramatically suppressed by sinensetin. Mechanistic investigation revealed that sinensetin suppressed NF-κB transcriptional activity in TNF-α– or influenza H1N1 virus–stimulated cells. Furthermore, sinensetin abrogated influenza H1N1 virus–induced activation of NF-κB, ERK1/2 MAPK, and p38 MAPK signaling.
In human chondrocytes, sinensetin decreased the secretion of inflammatory mediators such as COX-2, IL-6, iNOS, MMP13, and TNF-α in IL-1β-treated cells, and reversed the IL-1β-mediated downregulation of collagen type II.
Anticancer Pathways
Sinensetin, a citrus polymethoxylated flavone, has resurfaced as a multi-target natural product with promising anti-inflammatory and anticancer potential by affecting various cellular signaling pathways. It modulates core inflammatory and oncogenic pathways—including AMPK, NF-κB, MAPK, β-catenin, AKT, P53, and MKK6—to suppress proliferation, migration, and survival signaling while enhancing antioxidant defenses and dampening cytokines such as TNF-α and IL-6.
Sinensetin reduced the viability of breast cancer cells (MCF-7 and MDA-MB-231) by inducing apoptosis but did not affect the viability of normal mammary epithelial cells. Sinensetin also suppressed invasion and epithelial–mesenchymal transition (EMT) of breast cancer cells, accompanied by downregulation of β-catenin, LEF1, TCF1/TCF7, and TCF3/TCF7L1 at both the protein and mRNA levels. Treatment with a WNT agonist reversed the sinensetin-mediated inhibition of cell survival, migration, and EMT, suggesting that sinensetin targets WNT signaling or its downstream factors.
In hepatocellular carcinoma (HCC) in vitro studies, sinensetin significantly induced cell death in HepG2 cells, whereas the proliferation rate of Thle2 (normal human liver epithelial cells) was unaffected. HepG2 cells were not affected by apoptotic cell death; instead, autophagic cell death was induced through the p53-mediated AMPK/mTOR signaling pathway. Inhibition of p53 degradation led to both autophagy and apoptosis. However, sinensetin showed apoptosis induction in the p53-mutant Hep3B cell line.
In a murine xenograft tumor model, sinensetin inhibited the growth of HepG2/C3A human liver hepatoma cell-derived tumors and reduced expression levels of platelet/endothelial cell adhesion molecule-1 and VEGF. Sinensetin repressed VEGF expression by downregulating hypoxia-inducible factor expression. In cultured human umbilical vein endothelial cells, sinensetin increased apoptosis and repressed migration and tube formation. Sinensetin decreased the phosphorylation of VEGFR2 and inhibited the AKT signaling pathway.
In human T-cell lymphoma Jurkat cells, sinensetin significantly impeded cell proliferation in a dose-dependent and time-dependent manner. Sinensetin treatment triggered both apoptosis and autophagy. Apoptosis induction was related to a loss of mitochondrial membrane potential and to increased caspase-3/-8/-9 and poly(ADP-ribose) polymerase (PARP) cleavage. Sinensetin also induced autophagy, as evidenced by the formation of acidic vacuoles, upregulation of LC3-II and beclin-1, and downregulation of p62.
Studies in non-small cell lung cancer (NSCLC) suggest that sinensetin could serve as a specific MKK6 inhibitor, and this selectivity offers potential for therapeutic strategies in NSCLC when combined with other treatment modalities.
Vasorelaxant Mechanisms
In an in vitro precontraction aortic ring assay, sinensetin-stimulated relaxation was significantly reduced by inhibitors of nitric oxide synthase, cyclic GMP, soluble guanylate cyclase, cyclooxygenase, and multiple potassium and calcium channel blockers, as well as by muscarinic and β-adrenergic receptor blockers. Sinensetin was also active in reducing Ca2+ release from the sarcoplasmic reticulum (via IP3R) and in blocking calcium channels (VOCC). This demonstrates that the vasorelaxant effect of sinensetin involves the NO/sGC/cGMP pathway, calcium and potassium channels, and muscarinic and beta-adrenergic receptors.
Anti-dementia / Neuroprotective Mechanisms
In research exploring natural BACE1 inhibitors, sinensetin was identified among representative PMFs as a BACE1 inhibitor. Tangeretin exhibited the strongest BACE1 inhibition (IC50, 4.9 × 10−5 M), followed by nobiletin and sinensetin with IC50 values of 5.9 × 10−5 M and 6.3 × 10−5 M, respectively. All three compounds reacted in a non-competitive manner with the substrate. Previous studies have suggested the generation of intraneuronal amyloid-beta (Aβ) oligomers is an early event in the pathogenesis of Alzheimer's disease, and BACE1 catalyzes the rate-limiting step of Aβ generation, making it a prime target for Alzheimer's disease therapeutics.
Antidiabetic Mechanisms
Molecular docking analysis demonstrated that sinensetin interacted with the amino acid residues of α-glucosidase, potentially preventing substrate entry and decreasing the catalytic efficiency of α-glucosidase. Glycation assays showed that sinensetin stabilized the structure of bovine serum albumin (BSA) and strongly inhibited the formation of dityrosine, N′-formylkynurenine, and advanced glycation end products (AGEs). This study suggested sinensetin may have relevance to preventing and treating type 2 diabetes and related complications.
P-glycoprotein Inhibition
Sinensetin increased digoxin uptake in rats with significant increment relative to control in AUC0-t and Cmax, although weaker than verapamil as a positive control. The effects of several flavonoids including sinensetin on the pharmacokinetics of digoxin in rats were evaluated after administration of 0.25 mg/kg digoxin. Results disclosed significant increments in AUC0-t of 95.33% (p < 0.01) and Cmax of 25.85% (p < 0.05) caused by sinensetin. In addition, Vd/F and Cl/F of digoxin were also decreased after pre-administration with sinensetin.
5. Scientific Evidence by Area of Use
Important note on evidence level: As explicitly stated by the lead comprehensive review of sinensetin (Frontiers in Pharmacology, 2021), more detailed mechanistic studies are needed to understand its pharmacological effects, and more in vivo studies in various animal models including toxicity, pharmacokinetic, pharmacodynamic, and bioavailability studies are required to assess its efficacy and safety before submission to clinical studies. Across all areas below, no completed human clinical trials specifically on isolated sinensetin have been identified in the peer-reviewed literature as of the available sources. All evidence described is preclinical (in vitro and/or animal studies) unless otherwise noted.
5.1 Cancer (Anticancer Effects)
Sinensetin, found in Orthosiphon aristatus and several citrus fruits, has been found to possess strong anticancer activities with promising potency and minimal toxicity. Scientific attention to its anticancer activity dates to at least 1989.
Hepatocellular carcinoma (HCC): Sinensetin exhibits antiproliferative effects in HepG2 cells and induces apoptosis; molecular evidence of apoptotic activation was confirmed at both the mRNA and protein levels. A separate study confirmed that in sinensetin-treated HepG2 cells, autophagic cell death rather than classic apoptosis was induced through the p53-mediated AMPK/mTOR signaling pathway; inhibition of p53 degradation led to both autophagy and apoptosis. These are in vitro findings only.
Breast cancer: Anticancer effects of sinensetin through inhibition of the β-catenin pathway have been reported in breast cancer cells. Sinensetin reduced the viability of breast cancer cells (MCF-7 and MDA-MB-231) by inducing apoptosis but did not affect the viability of normal mammary epithelial cells. Evidence is limited to in vitro cell-line studies.
Non-small cell lung cancer (NSCLC): Sinensetin's molecular targets and potential therapeutic effects in NSCLC had largely remained unexplored until recent studies identifying it as a selective MKK6 inhibitor. Evidence remains at the preclinical stage.
T-cell lymphoma: In vitro, sinensetin induced cell death, apoptosis, and autophagy in Jurkat cells through activation of the reactive oxygen species/c-Jun N-terminal kinase pathway and by blocking the Akt/mTOR signaling pathways. This is cell-line evidence only.
Anti-angiogenesis: Among several PMFs, sinensetin exhibited the best anti-angiogenesis effect compared to nobiletin, hesperetin, scutellarein, neohesperidin, and naringin in HUVECs and zebrafish models. This represents in vitro / animal model evidence.
Cervical cancer (HeLa cells): A chloroform fraction extract of Citrus grandis leaf, identified to contain sinensetin among other PMFs, strongly decreased the survival rate of HeLa cells with an IC50 value of 56.54 μg/mL. The PMFs in the extract induced downregulation of anti-apoptotic Bcl-2 protein expression, resulting in proteolytic activation of caspases and PARP degradation. These results are from a mixed fraction, not isolated sinensetin.
Overall strength of anticancer evidence: Predominantly in vitro; multiple cell lines have been studied. One xenograft mouse model study demonstrated in vivo tumor suppression. No human clinical trials have been reported on isolated sinensetin.
5.2 Anti-inflammatory Effects
In cell-based studies, eupatorin and sinensetin inhibited iNOS and COX-2 expression and the production of NO (IC50 9.2 µM for sinensetin) and PGE2 (IC50 2.7 µM for sinensetin) in a dose-dependent manner. The compounds also inhibited TNF-α production (IC50 2.7 µM for sinensetin).
In inflammatory settings, sinensetin attenuates NF-κB activation, lowers pro-inflammatory cytokines (e.g., TNF-α, IL-6), and enhances antioxidant defenses, supporting its reported antioxidant, anti-bacterial, anti-viral, and anti-obesity properties.
Emerging clinical evidence from flavonoid-enriched orange juice interventions indicates antioxidant and anti-inflammatory effects, aligning with extensive preclinical data. However, this clinical evidence relates to orange juice broadly (containing multiple flavonoids), not to isolated sinensetin.
Overall strength of anti-inflammatory evidence: Reasonably strong in vitro and some in vivo (animal) evidence; key molecular targets (NF-κB, COX-2, iNOS) have been characterized. No isolated sinensetin human clinical trials identified.
5.3 Vasorelaxant and Antihypertensive Effects
Orthosiphon stamineus is an important traditional plant for the treatment of hypertension, and previous studies have demonstrated that the sinensetin content in O. stamineus is correlated with its vasorelaxant activity.
Diuretic activity has been documented in animal experiments after application of Orthosiphon extracts to rabbits and dogs, attributed in part to sinensetin, but clinical studies in humans did not prove significant diuretic activity. This represents a direct conflict between animal-model data and human clinical study findings—an important distinction for evaluating therapeutic utility.
Overall strength of vasorelaxant evidence: Preclinical (in vitro aortic ring model; animal models). The diuretic component of the activity was not confirmed in human clinical studies. More in vivo and human studies are needed.
5.4 Antidiabetic Effects
Sinensetin is considered a polymethoxyflavone most responsible for the biological activity of O. stamineus not only as an antihypertensive but also as an anticancer, antidiabetic, antimicrobial, anti-inflammatory, vasorelaxant, and antioxidant agent.
The antidiabetic mechanism involves α-glucosidase inhibition and AGE inhibition as described in Section 4. Orthosiphon aristatus is traditionally used in the treatment of diabetes, among other conditions. Evidence for sinensetin specifically in this context is from in vitro molecular docking and biochemical assays.
Overall strength of antidiabetic evidence: Preliminary, primarily in vitro. No human clinical trials for isolated sinensetin in diabetes have been identified.
5.5 Neuroprotective / Anti-dementia Effects
Although the beneficial effects of PMFs had been reported previously, the potential of their inhibitory activities against BACE1 in preventing and/or treating Alzheimer's disease (AD) was evaluated in vitro; sinensetin's activities as a BACE1 inhibitor were assessed alongside in silico docking analysis to determine its specific binding sites with human BACE1.
Sinensetin's IC50 for BACE1 inhibition was 6.3 × 10−5 M and its Ki was 3.8 × 10−5 M (it lowered Aβ generation in a dose-dependent manner, p < 0.001). This is biochemical/in vitro evidence only.
Overall strength of anti-dementia evidence: Very preliminary; in vitro BACE1 inhibition and in silico docking. No animal or human studies of sinensetin in dementia or Alzheimer's disease models have been identified in the reviewed sources.
5.6 Anti-obesity Effects
Sinensetin has been associated with anti-obesity and hypolipidemic properties in preclinical research. Its anti-obesity actions involve both lipolysis stimulation and modulation of adipogenesis; however, PMFs such as sinensetin have received increasing attention due to their multiple bioactivities, including metabolic regulatory effects, with mechanisms involving regulation of critical molecular targets and interaction with gut microbiota.
Overall strength of anti-obesity evidence: Preliminary, from in vitro cell-based studies and animal models. No isolated sinensetin human clinical trials identified.
5.7 Antimicrobial and Antitrypanosomal Effects
In vitro and in vivo studies showed that sinensetin possessed, among other activities, antimicrobial activity. Research has also characterized antitrypanosomal activity; pharmacological activities reviewed for sinensetin include antitrypanosomal activity along with its mechanisms of action in various disease states.
Overall strength of antimicrobial/antitrypanosomal evidence: In vitro only, as described in published reviews. No clinical human studies identified.
5.8 Urinary Tract Effects
Clinical studies in humans did not prove significant diuretic activity for Orthosiphon extracts, leading researchers to speculate that the traditional use of Orthosiphon extract for urinary tract infections may be related not to a pronounced diuretic effect, but more to an inhibitory effect against uropathogenic Escherichia coli (UPEC).
Overall strength of urinary tract evidence: The traditional use in the context of the whole plant is recognized by the EMA HMPC; however, the underlying mechanism and the specific contribution of sinensetin to these effects in humans remains unclear. Clinical evidence for the isolated compound is absent.
6. Body Systems and Health Areas Associated with Sinensetin
- Oncology/Cancer: Multiple cancer cell lines studied in vitro; one murine xenograft in vivo model for liver cancer.
- Cardiovascular system: Vasorelaxant, antihypertensive, and possible antihyperlipidemic effects studied preclinically.
- Immune system/Inflammation: Broad anti-inflammatory activity via NF-κB, COX-2, iNOS suppression, documented in vitro and in animal models.
- Metabolic health: Antidiabetic (α-glucosidase inhibition, AGE inhibition, glycemia) and anti-obesity effects at preclinical stage.
- Neurological system: BACE1 inhibition with potential relevance to Alzheimer's disease prevention; in vitro only.
- Renal/Urinary tract: Traditional use as diuretic and for urinary tract irrigation; recognized in EMA monograph for the parent plant. Human clinical evidence for the isolated compound is not established.
- Musculoskeletal system: Anti-inflammatory activity in human chondrocytes relevant to osteoarthritis and rheumatic conditions.
- Gastrointestinal: Preliminary data on epithelial barrier function and colitis models.
7. Dosage Forms and Dosages Reported in Studies
No standardized clinical dosing for isolated sinensetin in humans has been established. The following dosages and concentrations are those reported specifically in the reviewed scientific literature:
- In cell-based anti-inflammatory assays, sinensetin inhibited NO production with an IC50 of 9.2 µM and PGE2 with an IC50 of 2.7 µM.
- In human chondrocyte studies, treatment with 1 μg/mL (~2.7 μM) sinensetin exerted a protective effect against IL-1β-induced cytotoxicity, while concentrations ≥5 μg/mL (~13.4 μM) reduced cell viability.
- In the BACE1 inhibition assay, sinensetin had an IC50 of 6.3 × 10−5 M (Ki value of 3.8 × 10−5 M).
- In a rat pharmacokinetic study, the effects of sinensetin on digoxin pharmacokinetics were evaluated after administration of 0.25 mg/kg digoxin, with sinensetin producing a significant increment in AUC0-t of 95.33% (p < 0.01) and Cmax of 25.85% (p < 0.05).
- Cytotoxicity of sinensetin against 293T human embryonic kidney cells yielded IC50 values of 11.2 and 13.8 μg/mL (natural vs. reagent grade, respectively) by resazurin assay in vitro.
- For the parent plant (O. stamineus dried leaf), the EMA assessment report cites an infusion of 2–3 g of dried material in 150 mL of water, two to three times per day.
The traditional use recommendations of the EMA HMPC mainly refer to water extract, but hydroalcoholic extracts (ranging from 20 to 60% ethanol) are also accepted for drug registration in the EU.
8. Safety Considerations and Drug Interactions
General Toxicity Profile (Preclinical Data)
Many in vivo and in vitro studies have indicated that sinensetin not only showed good activity towards tumor cells, but also exerted minimal toxicity to normal cells according to the ratio of IC50 values, and possessed high selectivity.
Most of the cytotoxic effects assessed in the reviewed studies reported minimal cytotoxicity compared to other tested compounds and untreated controls.
More detailed mechanistic studies are needed to understand sinensetin's pharmacological effects. More in vivo studies in various animal models—including toxicity, pharmacokinetic, pharmacodynamic, and bioavailability studies—are required to assess its efficacy and safety before submission to clinical studies. This represents the consensus conclusion of the most comprehensive published review.
P-glycoprotein (P-gp) Inhibition and Drug Interactions
Findings on sinensetin were consistent with increment of rhodamine-123 accumulation in AML-2/D100 cells, reduced talinolol transport by P-gp from basolateral to apical side in a Caco-2 colon carcinoma cell monolayer model, and increased uptake of [3H] vincristine into adriamycin-resistant human myelogenous leukemia (K562/ADM) cells.
Sinensetin is capable of inhibiting P-glycoprotein (P-gp) efflux transporter and breast cancer resistance protein (BCRP), and has potential to serve as a flavonoid chemosensitizer.
These P-gp inhibitory properties carry important safety implications: sinensetin increased digoxin uptake in rats with significant increments in AUC0-t of 95.33% (p < 0.01) and Cmax of 25.85% (p < 0.05) compared with control after administration of 0.25 mg/kg digoxin. Vd/F and Cl/F of digoxin were also decreased after pre-administration with sinensetin. Because digoxin is a narrow-therapeutic-index cardiac glycoside and a standard P-gp substrate, this finding suggests that co-administration of sinensetin could significantly alter the bioavailability of drugs that are P-gp substrates, raising a clinically relevant pharmacokinetic interaction concern.
Concentration-Dependent Cytotoxicity in Normal Cells
In human chondrocyte studies, while concentrations of 1 μg/mL (~2.7 μM) exerted a protective effect, higher concentrations of sinensetin (≥5 μg/mL; ~13.4 μM) reduced cell viability. This indicates a concentration-dependent cytotoxic threshold in normal cells that has been documented in at least one cell type.
Traditional Plant Safety
The EMA HMPC monograph on the parent plant addresses contraindications, warnings, interactions, use in pregnancy and lactation, effects on ability to drive, undesirable effects, and overdose. These apply to the whole-herb preparation; the safety profile of isolated sinensetin in humans has not been formally established through clinical trials.
Evidence Gaps and Research Status
More detailed mechanistic studies are needed to understand sinensetin's pharmacological effects; more in vivo studies in various animal models including toxicity, pharmacokinetic, pharmacodynamic, and bioavailability studies are required to assess its efficacy and safety before submission to clinical studies. This is the explicit conclusion of the published scientific review literature. No human clinical trials on isolated sinensetin have been completed and reported in the peer-reviewed sources reviewed here. The results of in vivo and in vitro preclinical studies of PMFs have highlighted molecular mechanisms and signaling pathways for anti-inflammatory, anti-cancer, antidiabetic, anti-obesity, hepatoprotective, and neuroprotective effects, but further clinical trial investigation is necessary to validate these findings.
References
Go back